YM

Yael Margolin

Board Member at POINT Biopharma

Dr. Yael Margolin has more than 35 years of experience as a senior manager, CEO, and board member in venture capital and in the pharmaceutical and biotech industries, leading strategic and business planning, financing, team building, product development, and corporate partnerships. From 2005 to 2019, Dr. Margolin served as President, Chief Executive Officer, and director of Gamida Cell Ltd. (Nasdaq: GMDA), a clinical-stage biopharmaceutical company, leading the company from preclinical development through phase 3 international registration studies. Prior to that, Dr. Margolin was Vice President of Denali Ventures LLC, a venture capital firm focused on healthcare, and a program manager at Teva Pharmaceuticals. Dr. Margolin holds a BSc in biology and an MSc Cum Laude from the department of microbiology, both from Tel Aviv University in Israel, a Ph.D. from the department of membrane research at the Weitzman Institute of Science in Rehovot, Israel, and was a post-doctoral associate at the Yale University School of Medicine.

Timeline

  • Board Member

    Current role